Firenze, 27 March 2011 1 |1 | HIV and HCV in prisons: From evidence to action Firenze, ICAR 2011, 27 March 2011 Ralf Jürgens, Canada.

Slides:



Advertisements
Similar presentations
Meeting need and improving coverage workshop. Meeting need: calculating and improving coverage.
Advertisements

HIV in Europe Stockholm, 3.November 2009 Communication on combating HIV/AIDS in the EU and the neighbourhood - strategy and second action plan ( )
Workshop IV: Provision of Health Care The Impact of International Standards and Guidelines on prisoner health in Eastern and Central Europe Antalya, Turkey.
Turning the tide: Not without prisons! Promoting comprehensive national HIV responses.
Needle and syringe programmes in prisons
The U.S. President’s Emergency Plan for AIDS Relief The Evolving HIV Prevention Strategy for IDUs in PEPFAR Amb. Eric Goosby US Global AIDS Coordinator.
1 Overview of the 2003 Prison Rape Elimination Act (PREA) These materials were developed by The Moss Group, Inc.under cooperative agreement #03P21G1Y4.
Key Populations: Making Them Matter in the Global HIV Response Inextricable Links: HIV and Human Rights Kevin Osborne, LINKAGES Project Director 2 March.
1 Global AIDS Epidemic The first AIDS case was diagnosed in years later, 20 million people are dead and 37.8 million people (range: 34.6–42.3 million)
GAP Report 2014 Sex workers People left behind: Sex workers Link with the pdf, Sex workers.
GAP Report 2014 Prisoners People left behind: Prisoners Link with the pdf, Prisoners.
A Call for Action HIV/AIDS & Hepatitis C in Irish Prisons Irish Penal Reform Trust & Merchants Quay Ireland by Rick Lines, MA July 26, 2002.
1 On Point: making prison needle and syringe programs work in Canada January 23rd, 2014 Sandra Ka Hon Chu Canadian HIV/AIDS Legal Network.
Integrated responses to drugs and infections across European criminal justice systems Integrated responses to drugs and infections across European criminal.
Operational Approaches for Comprehensive Sex Worker Programmes An overview of Implementing Comprehensive HIV/STI Programmes with Sex Workers: Practical.
Topic 2 The prevalence of HIV/AIDS and its potential impact on individuals, communities and countries Slide 2.1.
HIV Prevention, treatment and care among people who inject drugs Fabienne Hariga, MD, MPH Senior HIV Adviser, UNODC Vienna.
Opiate Substitution Treatment and Harm Reduction in prisons: the Geneva model PD Dr Hans Wolff University Hospitals Geneva
HIV AIDS Section Fabienne Hariga Senior Adviser UNODC HIV AIDS section, Vienna Comprehensive package of interventions for HIV in prison settings AIDS 2012.
 Insufficient Reliable data in this region  Estimated people living with HIV  The number of new HIV infections in the region increased.
HIV/AIDS in Prison Settings Dr. Monica Beg HIV/AIDS Unit, United Nations Office on Drugs and Crime, Krakow, Poland September 27, 2004.
UNODC response to HIVAIDS Baltic Forum "Drug Control in the Baltic Region: New Challenges" September 2005 Vilnius Zhannat Kosmukhamedova, HIV/AIDS.
EngenderHealth/UNFPA Project – Ethiopia/Ukraine Strengthening the integration of HIV prevention in maternal health services. Increasing the capacity of.
Treatment of drug addiction in prisons
Overview of the State of the HIV Epidemic in Canada Regional Session on USA and Canada XIX International AIDS Conference Howard Njoo MD, MHSc, FRCPC Director-General.
Harm Reduction.
At the frontier of drug harm reduction Prisoners’ rights to health & safety David McDonald Visiting Fellow National Centre for Epidemiology and Population.
HIV/AIDS prevention and care among injecting drug users and in prison settings in Estonia, Latvia and Lithuania Signe ROTBERGA UNODC, Baltic States 5 November.
Results from the Spanish experience: A comprehensive approach to HIV and HCV in prisons MERCEDES GALLIZO LLAMAS Secretary-General of Spanish Prison Administration.
HARM REDUCTION RESPONSES TO DRUGS IN THE EUROPEAN UNION – FROM MARGIN TO MAINSTREAM 8 th Annual Meeting of the European Red Cross / Red Crescent Network.
Annual report 2010: the state of the drugs problem in Europe.
HIV Prevention and Treatment for Men who have sex with Men: Achievements and Challenges Ifeanyi Kelly Orazulike National Coordinator Sexual Minorities.
If I ruled the world… Presentation to Prisons and Beyond NOMS Prison Drug Strategy Unit, in association with the Federation of Drug & Alcohol Professionals.
A global perspective on scaling up harm reduction 2 nd National Harm Reduction Conference, Ukraine, March 2007 Dr Jos Perriens, Director Prevention.
Return on investment: How do whole societies benefit from improved services and coverage for key populations? Bradley Mathers Kirby Institute UNSW Australia.
Paradoxes and Problems in Preventing HIV Infection among Injecting Drug Users and Their Sexual Partners in Eastern Europe and Asia Don C. Des Jarlais,
Keep your promise to women and girls Violence against Women and Girls in National AIDS plans.
Harm Reduction International
Montreux, Switzerland, March 2007 New Data on Male Circumcision and HIV Prevention: Policy and Programme Implications New Data on Male Circumcision and.
School of Public Health and Community Medicine How policies and repressive law- enforcement fuel the HIV epidemic among people who inject drugs Professor.
Regional Videoconference Addressing Stigma and Discrimination of HIV/AIDS in Africa Thursday, April 2, 2009 UNAIDS Perspective Susan Timberlake, Senior.
Knowing your Epidemic: Designing Better Interventions in Prisons Deputy Commissioner Mary C. Chepkonga Kenya Prisons Service International AIDS Conference.
HIV AND INFANT FEEDING A FRAMEWORK FOR PRIORITY ACTIONS.
BEST PRACTICE PORTAL BEST PRACTICE PORTAL project presentation to the Scientific Committee Ferri et al Lisbon, 16th July 2010.
1 Background & history of the debate Geneva, 14 October 2009 Ralf Jürgens.
HIV/AIDS in Eastern Europe Setting the Stage for Prevention HIV/AIDS in Eastern Europe Setting the Stage for Prevention Thomas E. Novotny, MD, MPH April.
HIV Prevention, Treatment and Care in Prisons and other Closed Settings Ehab Salah Prisons and HIV Advisor UNODC, Vienna ICASA 2015 Harare, Zimbabwe 2.
Effective HIV & SRH Responses among Key Populations Module 2: The Comprehensive Package of Programmes and Services.
HEALTH CARE, DRUG USE AND EPIDEMIOLOGY OF INFECTIOUS DISEASES IN PRISONS SYSTEM OF LITHUANIA BIRUTE SEMENAITE, VLADAS RIMGAUDAS KASPERUNAS, MEDICAL DIVISION.
19 June 2007 Prison & Health Expert Meeting Paris Drugs and prisons DG SANCO C4 N. GRENIER.
From evidence to commitment to action: implementing HIV prevention measures in prisons in Ukraine XVI International AIDS Conference Toronto, 15 August.
Skills Building Workshop – Conducting Situation and Needs Assessments in Prison Settings HIV and AIDS in Prisons Overview of Issues and Challenges Brian.
The Canadian Correctional Public Health Program Prison Health Expert Group Sixth Meeting Oslo, Norway September 30, 2008.
Health in Prisons Project Oslo, 24 November 2009 Lars Moller Regional Adviser a.i. World Health Organization Regional Office for Europe Health in Prisons.
2008 International AIDS Conference UNGASS reporting Matthew Warner-Smith Monitoring and Evaluation Division UNAIDS 2008 International AIDS Conference Satellite.
Harm reduction evidence: Eastern Europe and Central Asia Raminta Stuikyte Central and Eastern European Harm Reduction Network.
1 A Public Health and Human Rights Imperative: The Case for Prison Needle and Syringe Programs XVII International AIDS Conference Tuesday, August 5, 2008.
MODULE 3 Harm reduction advocacy
IAS Satellite Session 25th July 2017 Daniel Were, PhD
Dr. Monica Beg, Chief, HIV/AIDS Section, UNODC
Fabienne Hariga Senior Adviser, HIV/AIDS Section
New Data on Male Circumcision and HIV Prevention: Policy and Programme Implications WHO/UNAIDS Technical Consultation on Male Circumcision and HIV.
Government of Swaziland
Evidence for Action: Effectiveness of HIV/AIDS interventions in prison settings In 2005, WHO commissioned a review of the evidence of the effectiveness.
Prisons and TB in Europe
People who inject drugs
Access to Services in Prison and Beyond
National Programme for limiting spread of HIV/AIDS in Latvia 2008–2012
Towards a Conducive Legal and Structural Environment
Showing throughout the event
Presentation transcript:

Firenze, 27 March |1 | HIV and HCV in prisons: From evidence to action Firenze, ICAR 2011, 27 March 2011 Ralf Jürgens, Canada

Firenze, 27 March |2 | Acknowledgements Annette Verster & Andrew Ball (WHO) Peer reviewers UNODC, UNAIDS

Firenze, 27 March |3 | Background HIV rates in prisons & pre-trial detention are much higher than in the community outside prisons Even where HIV rates remain low, HCV rates are high – often exceeding 50% Very high co-infection rates (HCV co-infection observed in more than 90% of HIV-positive prisoners in Genova) Sources: WHO, UNODC, UNAIDS, 2007; Jürgens, Ball, Verster, 2009; Pontali, Ferrari, 2008; Dolan et al., 2007, Macalino et al., 2004, Dolan & Wodak, 1999; MacDonald, 2005; Bobrik et al., 2005; Taylor et al., 1995

Firenze, 27 March |4 | HIV prevalence in selected countries % % Brazil % 16-32% (5 regions) Ukraine % 4-22% Indonesia % 28.4% Viet Nam % Up to 4% Russian Federation % Up to 14% Spain 0.3% 7% Italy % 1.9% USA % 1-12% Canada Est. Adult HIV Prevalence HIV Prevalence in Prisons Country

Firenze, 27 March |5 | Background: risk behaviours Risk behaviours are prevalent in prisons – Consensual & non consensual sex – Injecting drug use – Tattooing – Sharing of razors and toothbrushes

Firenze, 27 March |6 | Background: sexual activity Difficult to obtain reliable data – Methodological and ethical challenges – Sex violates prison regulations – Feelings of shame and homophobia: prisoners decline to participate in studies – Admitting to having been raped in prison goes against prisoner code Nevertheless, evidence is clear: consensual and non- consensual sex do occur

Firenze, 27 March |7 | Background: sexual activity Africa: (Nigeria, Zambia, Mozambique): 4-5.5% South America: 10% (Brazil) Asia: 20% (Thailand) Central & Eastern Europe: – Russia (9.7-12%; much higher among long-term prisoners) – Slovakia: 19% of female, 5.6% of adult male, 8.3% of juveniles – Slovenia: 19.3% – Hungary: 9% – Armenia: 2.9% penetrative (36% against their will) Western Europe, Canada, Australia: 1-12% among males, up to 37% among females Source: WHO, UNODC, UNAIDS, 2007

Firenze, 27 March |8 | Background: drug use in prisons Drugs can and do enter into prisons Many prisoners are in prison because of offences related to drugs, and find a way to use inside Some discontinue using drugs in prisons Other prisoners start using (and/or injecting) drugs in prison No country has been able to stop drug use in prisons

Firenze, 27 March |9 | Injecting & needle sharing in prison

Firenze, 27 March | What could happen – what we can prevent Extensive HIV transmission can occur in prisons, significantly contributing to the spread of HIV among the general population. Thailand: HIV prevalence rate among injectors rose from a negligible percentage to over 40% between Jan & Sept 2008, fuelled by transmission of HIV in prisons. Six studies among people who inject drugs in Thailand found that imprisonment was associated significantly with HIV infection.

Firenze, 27 March | What could happen – what we can prevent Outbreaks of HIV in prisons have been documented in a number of countries, incl Scotland, Australia, Lithuania, and Russia. In Lithuania, in May 2002 the number of new HIV-positive test results among prisoners found in a two-week period equalled all the cases of HIV identified in the entire country during all of the previous years combined. 284 prisoners (15% of the prison population) were diagnosed HIV- positive between May and August 2002.

Firenze, 27 March | Prison conditions contribute to the problem Severe overcrowding Lack of work and meaningful activities Decaying physical infrastructure Lack of adequate medical care Lack of nutritious food & clean water Abuse & corruption Prisoner-on-prisoner violence

Firenze, 27 March |

Firenze, 27 March |

Firenze, 27 March | Public health implications 1.Health of prisoners = issue of public health concern 2.All people in Italy would benefit from enhancing the health of prisoners and reducing the incidence of communicable diseases prisoners and their families prison staff the families outside prison 3. Communicable diseases transmitted in prison do not remain there.

Firenze, 27 March | Interventions to address HIV in prisons We know what works – and what does not work: – WHO/UNODC/UNAIDS Evidence for Action Papers: Interventions to Address HIV in Prisons – Jürgens R, Ball A, Verster A. Interventions to reduce HIV transmission related to injecting drug use in prison. Lancet Infect Dis 2009; 9(1): International expert & UN consensus since 1993: HIV & HCV prevention & treatment in prisons are essential, for public health & human rights

Firenze, 27 March | Education and information Information & education programs result in increased knowledge (eg, Vaz, Gloyd & Trindade, 1996) However, evidence of effect of increased knowledge on behaviour is limited (Braithwaite, Hammett & Mayberry, 1996) Peer education is more effective (Grinstead et al, 1999) Education is not enough

Firenze, 27 March | Prevention of sexual transmission Providing condoms is feasible in prison settings No security problems or other negative consequences Prisoners use condoms when condoms are easily and discreetly accessible - prisoners should never have to ask for condoms or seen by others when they take a condom Source: WHO, UNODC, UNAIDS, 2007; Correctional Service Canada, 1999; Dolan, Lowe & Shearer, 2004; May and Williams, 2002; Yap et al., 2007)

Firenze, 27 March | Prevention of sexual transmission Need for measures to combat rape and sexual abuse –Changing the institutional culture tolerating sexual violence –Multi-pronged approaches are needed: Prevention efforts (prisoners education, classification, structural interventions such as better lighting, better shower and sleeping arrangements) Staff training, investigation, prosecution, victim services Documenting incidents Post Exposure Prophylaxis (PEP) should be available

Firenze, 27 March | Needle and syringe programmes (NSPs) NSPs in the community exist in most countries, including Italy Studies have found NSPs – to be effective in reducing HIV spread – do not lead to increased drug use First established in prisons in Switzerland in 1992 Since then, introduced in 12 countries in western and eastern Europe and central Asia

Firenze, 27 March | NSPs in prisons Today, NSPs are operating in a growing number of countries, in all types of prisons and prison systems: – In well funded prison systems (eg, Spain, Switzerland, Germany) and severely under-funded prison systems (eg Moldova, Iran) – In institutions with drastically different physical arrangements for the housing of prisoners, from single cell to barracks – In prisons of all security classifications and sizes – In men’s and women’s institutions

Firenze, 27 March | Prison Colony 18, Branesti, Moldova

Firenze, 27 March | Evidence NSPs PrisonIncidence HIV&HCV Needle sharingDrug useInjecting Am Hasenburg (D) No increase Basauri (Es) No HIVNo increase Hannoversand (D) No increase Hindelbank (CH) No HIVDecreaseNo increase Lehrter Strasse & Lichtenburg (D) No HIV but HCVNo increase Linger 1 (D) No HIVNo increase Realta (CH) No HIVSingle casesDecreaseNo increase Vechta (D) No HIVNo increase Vierlande (D) No HIVLittle change or reduction No increase (Stöver & Nelles, 2003; Stark et al., 2005; Rutter et al., 2001)

Firenze, 27 March | Evidence NSPs No negative consequences – No increase in drug use or injecting – needles are not used as weapons Increased referral to drug dependence treatment Increased staff safety

Firenze, 27 March | How is needle exchange done? PNEPs utilize various methods for distributing injecting equipment – Hand-to-hand exchange by nurses and/or the prison physician – Distribution by one-for-one automated syringe dispensing machine – Distribution by prisoner trained as peer outreach workers – Distribution by external NGOs or other health professional who come into the prison for this purpose

Firenze, 27 March |

Firenze, 27 March | Determinants of success Prisoners must have confidential, easy access Prisoners must have access to the type of injecting equipment they want and need Support of the prison administration, staff, and prisoners is crucial (educational workshops for these groups should be part of implementation of NSPs) Start with pilot project in a few prisons, monitor and evaluate, then scale up

Firenze, 27 March | Recommendations NSPs in prisons WHO,UNODC, UNAIDS recommend: – Introduce NSPs urgently – Provide easy and confidential access to NSPs – Distribution through peers or NGOs

Firenze, 27 March | Could providing NSP send out the wrong message? Could it be seen as “being soft” on drug use? – As tolerating or condoning drug use in prisons? – As giving up the fight against drugs in prisons? No: drug use remains illegal and measures to continue fighting drugs in prisons continue But the fight against HIV is equally important Not taking evidence-based measures would mean condoning the spread of HIV among prisoners and ultimately to the community outside prisons

Firenze, 27 March | How much do NSPs in prisons cost? Very little – see Moldova example Cost effective – every euro spent on prison NSP saves many euros that would otherwise have to be spent on treatment of infectious diseases

Firenze, 27 March | Could providing bleach be enough? Studies have shown that providing bleach in prisons for decontamination purposes is feasible and does not compromise security But : Doubts about effectiveness – Conditions in prisons reduce probability of effective decontamination → Bleach programmes cannot replace NSPs Provide information on limited effectiveness Continue efforts to introduce NSPs

Firenze, 27 March | Is providing NSPs enough? NSPs are important component of efforts to reduce risk of HIV through injecting But alone they are not enough to eliminate the risk Effective, evidence-based drug dependence treatment is also needed, in particular methadone maintenance treatment (MMT)

Firenze, 27 March | Evidence: MMT in prisons MMT is available in growing number of countries and is most effective treatment for opioid dependence – reduced used of opioids, reduced mortality, reduced HIV risk behaviours, reduced criminal activity MMT in prisons is feasible and effective – most important benefit: reduced injecting drug use and associated needle sharing, if correct dose & length of treatment

Firenze, 27 March | Evidence: MMT in prisons Additional proven benefits of MMT in prison, for prison systems, society, and prisoners: – facilitates entry and retention in post-release treatment – decreases re-incarceration – positive effect on institutional behaviour – helps reduce risk of overdose upon release No negative side effects : – no problems for security & no violent behaviour – risk of diversion has been successfully addressed

Firenze, 27 March | Recommendations: MMT in prisons WHO, UNODC & UNAIDS recommend: – introduce and scale up MMT urgently in prisons – ensure that those on MMT in the community can continue MMT upon arrest and imprisonment

Firenze, 27 March | NSP & MMT: Learning from Spain Spain introduced and scaled up both MMT and NSPs This has resulted in significant decreases in HIV and HCV prevalence and incidence

Firenze, 27 March | HIV prevalence in Spanish prisons 46% of prisoners had a history of injecting drug use

Firenze, 27 March | Prisoners on MMT in Spanish prisons 11%

Firenze, 27 March | Evolution of Needle Exchange Programs

Firenze, 27 March | Conversions to HIV and HCV

Firenze, 27 March | Could we do sth else instead of NSP & MMT? Other measures would not be as effective Drug interdiction efforts are very costly They only reduce, but do not completely eliminate drug use in prisons

Firenze, 27 March | Drug demand & supply reduction measures Some systems have vastly expanded drug interdiction measures (drug dogs, modern drug detection analysis, urinalysis, “drug-free units”, etc) Drug use has remained high Improving documentation & evaluation of these measures should be a priority Prison systems with drug testing programs should reconsider testing for cannabis

Firenze, 27 March | HIV in prisons: other necessary steps Pro-actively offer (and recommend) HIV and HCV testing Ensure uninterrupted treatment Reduce overcrowding & improve prison conditions Provide work & other meaningful activities for prisoners

Firenze, 27 March | HIV in prisons: other necessary steps Provide non-custodial alternatives for people convicted of offences directly related to their drug dependence (possession of amounts for personal use or petty crimes committed to support drug use) “Governments may … wish to review their penal admission policies, particularly where drug abusers are concerned, in the light of the AIDS epidemic and its impact on prisons.” (WHO, 1987)

Firenze, 27 March | Conclusion: From evidence to action All prisoners have the right to receive … preventive measures equivalent to [those] available in the community” (WHO, 1993) Time to move from evidence to action in Italy : access to condoms, NSPs, MMT, voluntary HIV & HCV testing & treatment, as part of comprehensive HIV & HCV strategy for prisons and pre-trial detention, is urgently needed for prisoners